GlassScriptPhysician profile
Patrick Edward Dreyer
NPI 1497127054
$2,675.31
in general payments reported to CMS, 2019-2025
28 companies · $26.00 in 2025
The $26.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $942 · 2021: $332 · 2022: $178 · 2024: $16.06 · 2025: $26.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $42.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $42.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $551.89 | 2019-2021 | |
| Incyte Corporation | $345.81 | 2019-2020 | |
| Pfizer INC. | $261.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $214.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $146.38 | 2019-2020 | |
| Dova Pharmaceuticals | $125.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $107.66 | 2020-2021 | |
| Gilead Sciences, INC. | $106.25 | 2022 | |
| Janssen Biotech, INC. | $97.29 | 2020-2021 | |
| Eisai INC. | $90.75 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $86.89 | 2019-2020 | |
| Astellas Pharma US INC | $56.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $56.08 | 2020-2021 | |
| Abbvie INC. | $55.10 | 2020-2021 | |
| Beigene USA, INC. | $50.00 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $40.15 | 2019 | |
| Genzyme Corporation | $39.93 | 2019-2020 | |
| Exelixis INC. | $37.67 | 2019-2020 | |
| Advanced Accelerator Applications | $35.00 | 2020 | |
| Foundation Medicine, INC. | $24.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.15 | 2020 | |
| Novocure INC. | $22.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.80 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.20 | 2021 | |
| Genentech USA, INC. | $19.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.06 | 2024 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $12.70 | 2020 | |
| Lilly USA, LLC | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dreyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.